Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

Next Previous
X
Search
Trial Profile

An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belzutifan (Primary) ; Lenvatinib (Primary) ; Cabozantinib
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms LITESPARK-011
  • Sponsors Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 18 Jul 2024 Planned End Date changed from 23 Dec 2024 to 11 Feb 2026.
    • 18 Jul 2024 Planned primary completion date changed from 23 Dec 2024 to 11 Feb 2026.
    • 11 Aug 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top